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FIRST CLINICAL CASE REPORTV348I mutation in UL23 gene of human herpesvirus 1 in a case of herpetic
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della Scienza, Turin, ItalyAbstractWe herein report the case of a young immunocompetent adult patient with a rapidly fatal haemophagocytic lymphohistiocytosis syndrome
related to human herpesvirus 1 (HHV-1) infection, with herpetic hepatitis and persistent high-level viraemia despite treatment with acyclovir.
Haemophagocytic lymphohistiocytosis was confirmed in the patient’s spleen and bone marrow. HHV-1 DNA was extracted from whole
blood and liver biopsy and the UL23 gene was sequenced. A V348I natural polymorphism of the TK protein was found in blood and liver
specimens. Further studies are needed to investigate the role of this polymorphism in the development of systemic immune dysregulation.
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E-mail: silvia.corcione@unito.itIntroductionHuman herpesvirus (HHV) hepatitis is a rare disease usually
affecting immunocompromised patients; it can progress rapidly
with severe complications [1]. There are several reports
describing the development of haemophagocytic lymphohis-
tiocytosis (HLH) syndrome secondary to primary HHV in-
fections, and these cases are usually associated with a high
mortality rate [2]. HLH is a life-threatening condition that re-
sults from the uncontrolled activation of the immune system. It
was first described in 1939 by Scott et al. [3,4].
Knowledge regarding HLH pathogenesis, clinical presenta-
tion, diagnostic criteria and treatment options comes from
literature on paediatric patients; thus the prompt recognition of
HLH is sometimes difficult [5]. According to the Histiocyte
Society, HLH can be classified as primary or secondary [6]:This is an open access artiprimary HLH is autosomal recessive and usually presents in
childhood, whilst secondary HLH may result from immuno-
logical activation by malignancies, autoimmune disorders or
infections, of which viruses—particularly human herpesvirus 1
(HHV-1) and human herpesvirus 2 (HHV-2)—are among the
most common inducers [7].
Currently, the standard therapy for the management of
HHV-1 infections includes acyclovir (ACV). Drug-resistant
HHV-1 isolates are frequently recovered from immunocom-
promised patients. Genotypic characterization of drug-resistant
isolates can reveal mutations located in the UL23 gene which
encodes the viral thymidine kinase (TK), and mutations in this
gene result in resistance to ACV. UL23 gene mutations have
been reported in 95% of clinical isolates exhibiting ACV resis-
tance [8]; in particular, these mutations consisted of deletions/
insertions or substitutions of nucleotides leading to frameshift
reading, resulting in the synthesis of a truncated non-functional
enzyme [9]. The most important sites involved in the enzyme
activity are the ATP-binding site (aa 51–63), the nucleoside-
binding site (aa 168–176), and six highly conserved regions:
site 1 (aa 56–62), site 2 (aa 83–88), site 3 (aa 162–164), site 4
(aa 171–173), site 5 (aa 216–222), and site 6 (aa 284–289). In
particular, the substrate nucleoside-binding site, the conservedNew Microbe and New Infect 2019; 29: 100529
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frequently reported mutations in ACV-resistant clinical isolates
[8]. The main mutations associated with ACV-resistance are:
R51W, G56S/V, P57H, H58R/L, G59R/V, G61V, K62N, T63A/I/
S, D162A, R163H, A168T, P173L/R, A175V and R176Q.
Genotypic characterization of HHV-1 clinical isolates revealed a
high degree of polymorphism in the UL23 gene outside the
active site of the enzyme not associated with resistance [8,10].
We report here the case of a young immunocompetent
woman who developed a fatal herpetic hepatitis with persis-
tently high level HHV-1 viraemia, followed by haemophagocytic
lymphohistiocytosis syndrome. Moreover, we sequenced the
HHV-1 UL23 gene from blood and tissue samples to look for
ACV resistance.
Case description
We report here the case of a 22-year-old female admitted to
the emergency department of a peripheral hospital with 1-week
history of pharyngeal pain, prolonged fever, right-side abdomen
tenderness, thick white vaginal discharge, and dysuria partially
responsive to antibiotic treatment.
On admission she was febrile (temperature 38.0°C), with
pulse 115/minute, respiratory rate 14/minute, and blood pres-
sure 115/70 mmHg. Clinical examination was remarkable for
erythematous pharyngitis, bilateral cervical and axillary lymph-
adenopathy, watery painful blisters and multiple tender vaginal
ulcers. On laboratory exams, blood count revealed a reduction
in total white blood cells (WBCs) due to absolute neutropenia
(neutrophil count 800/mm3) and thrombocytopenia (113 000/
mm3); the haemoglobin level was normal.
At the time of admission to the ER, liver function test
showed elevated levels of alanine aminotransferase (ALT) and
aspartate aminotransferase (AST) to 270 UI/L and 200 UI/L,
respectively; cholestasis enzymes and international normalized
ratio (INR) were within the reference range. Renal function was
within normal limits. Abdominal ultrasound and computed to-
mography (CT) showed an enlarged liver and spleen with as-
cites and pelvic effusions consistent with acute hepatitis. Five
hours after hospital admission, repeat blood tests showed aTABLE 1. Biochemical analysis performed during the patient’s hos
Day 1 from hospital admission Day 2 Da
WBC (109/L) 900 2000 740
Hb (g/dL) 10.2 10.6 8.6
PLT (109/L) 91 000 88 000 84
AST/ALT (UI/L) 807/453 3076/1280 494
BIL (mg/dL) 1.6 2.2 2.2
INR 2.2 1.8 1.7
PCT (μg/L) 11 12 13
WBC, white cell blood count; Hb, haemoglobin; PLTS, platelets; BIL, bilirubin; PCT, procalc
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L, respectively, and with acute hepatitis suspected the patient
was transferred to the referral hospital.
At the referral hospital the patient required respiratory
support due to progressive dyspnoea, and she was transferred
to the intensive care unit (ICU). On clinical exam, she was
febrile, dyspnoeic, and laboratory tests revealed a worsening of
thrombocytopenia, new onset of renal failure, and further in-
creases in AST and ALT (4200 UI/L and 1300 UI/L, respec-
tively). Chest and abdomen CT scan confirmed mild
homogeneous liver and spleen enlargement, mild ascites and
initial alveolar pulmonary oedema.
Serological and microbiological tests were performed
(Tables 1 and 2), and empirical broad-spectrum antibiotics—
piperacillin/tazobactam 4.5 g every 8 h and levofloxacin 750 mg
once daily—were started, together with acyclovir 10 mg/kg
every 8 h. All exams were negative except for whole-blood
real-time PCR targeting HHV-1 DNA polymerase. Blood
HHV-1 DNA was >5 000 000 cp/mL, supporting the hypothesis
of primary HHV-1 infection with severe related hepatitis. HLH-
related HHV-1 infection was suspected as four clinical diag-
nostic criteria were fulfilled [5]: fever, splenomegaly, leukopenia
and thrombocytopenia in the peripheral blood.
Laboratory findings on day 3 from admission indicated
sharply worsening clinical features with multiorgan failure, and
the patient was started on haemodialysis and supportive
treatment. Antibiotic treatment was implemented with vanco-
mycin 1 g every 12 h and caspofungin at standard dosage. A
rectal swab was positive for a multidrug-resistant Acinetobacter
baumannii; blood cultures were repeatedly negative. Blood
HHV-1 DNA was persistently high despite intravenous
acyclovir (Table 2).
After 10 days of ICU stay, the patient developed an acute
respiratory distress syndrome. Bronchoalveolar lavage cul-
ture was positive for carbapenemase-producing Klebsiella
pneumoniae (CP-Kp), and chest radiographs showed extensive
right parenchymal consolidation. Due to her progressively
worsening condition and multiorgan failure, the patient died
on day 15.pital stay
y 3 Day 5 Day 7 Day 10 Day 15
0 14 000 15 000 18 000 1900
8.9 8.3 10.4 9.3
000 51 000 122 000 (T) 71 000 43 000
6/1710 4700/1300 800/274 330/180 200/110
3 5 8 11
1.5 1.1 1.1 1.6
– 6 3 1
itonin; INR, international normalized ratio.
nses/by-nc-nd/4.0/).




admission Day 5 Day 10 Day 15
HHV-1 DNA (cp/
mL)
– – 5 000 000 5 000 000 –
HHV-2 DNA (cp/
mL)
– – neg – –
HHV-1/2 DNA
genital swab
neg – – – –
Treponema Ig neg – – – –
Parvovirus IgM/
IgG
neg – – – –
Brucella IgM/IgG neg – – – –
Leishmania Ab neg – – – –
CMV DNA (cp/
mL)
neg – – – –
Anti-HCV neg – – – –
HBsAg neg – – – –
HIV p24/Ab1-2 neg – – – –
ASLOT (UI/mL) neg – – – –
Blood cultures neg neg – neg –
Urine culture neg neg neg Neg CP-kp
Bal – – – – CP-Kp;
Acinetobacter
MDR
Rectal swab – neg – – Cp-KP
ASLOT, antistreptolysin O titre; BAL, bronchoalveolar lavage; CP-Kp,
carbapenemase-producing Klebsiella pneumoniae; Acinetobacter MDR: multi-drug-
resistant Acinetobacter spp; NEG, negative.
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was performed. This revealed an enlarged liver consistent with
acute liver failure, with multiple foci of confluent necrosis
across multiple lobules consistent with HLH; moreover, HLH
was confirmed in the spleen and bone-marrow tissue. Immu-
nohistochemical analysis revealed HHV-1 positivity in the liver
within a large number of liver-cell nuclei.
Both whole blood and liver biopsy specimens were analysed
for HHV-1 mutation conferring resistance to acyclovir.HHV-1 DNA detection and UL23 gene
sequencingGiven the persistently high viraemia, HHV-1 DNA was
extracted from whole blood and liver biopsy and the UL23 gene
was sequenced.HHV-1 DNA extraction from whole blood
and liver biopsyViral DNA was purified from whole-blood specimens using the
automated QIAsymphony SP/AS instrument (Qiagen, France),
according to the manufacturer’s instructions. Tissue specimens
were formalin-fixed. For DNA extraction, sections (thickness 6
μm) were washed with ethanol and distilled water and incu-
bated with 400 μL of Buffer ATL (Qiagen, France) and 20 μL ofThis is an open access articproteinase K (Qiagen, France) at 56°C with shaking at
1000 rpm until the tissue was completely lysed; 200 μL of the
supernatant were collected for nucleic acid extraction per-
formed using the QIAsymphony SP/AS instrument. In order to
quantify the viral load in whole blood, DNA samples were
evaluated by 7500 Fast Dx Real Time PCR (Applied Biosystems,
Monza, Italy) using the HSV1 ELITe MGB Kit (ELITechGroup,
Molecular Diagnostics, Turin, Italy), according to the manufac-
turer’s instructions.
Sequencing of the UL23 gene of HHV-1 from whole-
blood and liver-biopsy specimens
Three primer sets, previously optimized in PCR reactions by da
Silva and colleagues, were used to amplify the HHV-1 UL23
region (1244 bp) from whole-blood and liver-biopsy specimens
[11]. Amplification was performed on a 7500 Fast Dx Real Time
PCR instrument (Applied Biosystems, Monza, Italy) under the
following conditions: 50 μL reaction volume consisted of 10 μL
DNA, 1 x Kapa Taq Ready Mix (0.05 U/μL of Taq DNA po-
lymerase, 2 x reaction buffer with 3.0 mM MgCl2, 0.4 mM each
dNTP; Kapa Biosystems, Boston, MA, USA) and primers 0.3 μM
(forward/reverse). The programme for cycling was as follows:
denaturation at 95°C for 5 min, followed by 45 cycles of 95°C
for 30 s, 55°C for 45 s, and 72°C for 40 s. The final extension
was done at 72°C for 10 min. Amplicons were analysed by
electrophoresis on a 2% agarose gel system and PCR products
with expected sizes were purified using reagents and protocols
of the High Pure PCR Product Purification Kit (Roche, Man-
nheim, Germany). The resulting purified products were
sequenced using the ABI Prism BigDye Terminator version 1.1
Ready Reaction mix (0.5 μL BigDye, 0.75 μL reaction buffer,
Applied Biosystems, Foster City, CA, USA). In particular, PCR
products were sequenced using the same three primer sets
used for amplification (2 μM forward/reverse primers). The
programme for cycling was as follows: 25 cycles of 95°C for 10
s, 50°C for 5 s and 60°C for 4 min. Amplicons were capillary
sequenced on an Applied Biosystems 3130xl Genetic Analyzer
(Life Technologies, Carlsbad, CA, USA).
Sequence analysis of the HHV-1 UL23 gene for detection of
mutations associated with acyclovir resistance was performed.
HHV-1 sequences were manually checked in the BioEdit v. 7.2.5
software. Nucleotide sequence alignments were performed
using a reference sequence (strain HSV-1 I4-2, GenBank
Accession Number: AB078742.1) obtained by NCBI database.
Alignments were confirmed using the Mutation Resistance
Analyzer (MRA) online HHV-1 drug resistance mutations tool,
which compares submitted sequences via BLAST to the refer-
ence sequence of UL23. Both whole-blood and liver-biopsy
specimens were found to have the same UL23 mutations, in
particular the V348I mutation.© 2019 The Author(s). Published by Elsevier Ltd, NMNI, 29, 100529
le under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
4 New Microbes and New Infections, Volume 29 Number C, --- 2019 NMNIDiscussionIt is well known that systemic infections can lead to complica-
tions such as HLH, and several studies have reported viral in-
fections as the leading infectious triggers of HLH [12–16].
Disseminated HHV-1 infection usually occurs in immunocom-
promised patients, but has also been described in immuno-
competent hosts; reports have described four of five patients
with HSV-related HLH as immunocompetent. Clearing the
infection trigger is the mainstay to decrease hyperimmune
activation in patients with secondary HLH [17]. However, with
the exception of HLH associated with human
gammaherpesvirus-4, there is little evidence regarding the sig-
nificance of a combined approach with immunosuppressive
therapy in virus-associated HLH, and further data are needed to
establish the optimal treatments for virus-associated HLH
[18,19].
More recently, a modification in the diagnostic criteria—
with three clinical findings plus one immune marker—to ach-
ieve diagnosis has been proposed [20]. In our case the presence
of fever, pancytopenia, spleen enlargement plus hyper-
triglyceridaemia fulfilled the diagnosis. Moreover, clinical sus-
picion was supported by histological confirmation.
Our patient had persistently high viraemia despite the
prompt start of acyclovir treatment. Therefore, we sequenced
HHV-1 UL23 gene from blood and tissue samples to look for
acyclovir resistance, but no mutations known to be associated
with acyclovir resistance were reported. Interestingly, we
found a V348I mutation that represents a natural polymorphism
of the TK protein hitherto not reported as related to acyclovir
resistance. Although there are no data available about the
clinical relevance of the V348I mutation, our patient had
persistently high viraemia and she rapidly developed HLH,
suggesting that the V348I mutation could be related to a higher
HHV-1 virulence, which may more easily trigger the systemic
immune dysregulation.
In conclusion, this is the first report describing a V348I
mutation in a patient with disseminated HHV-1 infection,
herpetic hepatitis and HLH. So far, there are no data
regarding the role of this mutation in clinical practice. More
data are therefore needed to correlate this mutation with the
rapid and fatal development of HLH related to HHV-1
infection.Transparency declarationThe authors have no conflicts of interest to declare. No funding
was received for the study.© 2019 The Author(s). Published by Elsevier Ltd, NMNI, 29, 100529
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